S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
Are These Consumer Staples Too Cheap for Investors To Ignore?
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
3 Reasons This Tech Giant Is Going Back To Highs
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
Are These Consumer Staples Too Cheap for Investors To Ignore?
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
3 Reasons This Tech Giant Is Going Back To Highs
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
Are These Consumer Staples Too Cheap for Investors To Ignore?
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
3 Reasons This Tech Giant Is Going Back To Highs
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
Are These Consumer Staples Too Cheap for Investors To Ignore?
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
3 Reasons This Tech Giant Is Going Back To Highs
NASDAQ:EWTX

Edgewise Therapeutics (EWTX) Stock Forecast, Price & News

$6.20
+0.03 (+0.49%)
(As of 09/20/2023 ET)
Compare
Today's Range
$6.08
$6.39
50-Day Range
$6.17
$7.69
52-Week Range
$5.53
$11.48
Volume
70,388 shs
Average Volume
128,432 shs
Market Capitalization
$393.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.00

Edgewise Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
335.5% Upside
$27.00 Price Target
Short Interest
Bearish
13.91% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.01mentions of Edgewise Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.58) to ($1.96) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.72 out of 5 stars

Medical Sector

816th out of 962 stocks

Pharmaceutical Preparations Industry

387th out of 450 stocks


EWTX stock logo

About Edgewise Therapeutics (NASDAQ:EWTX) Stock

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company also develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The Company was incorporated in 2017 and is headquartered in Boulder, Colorado.

EWTX Price History

EWTX Stock News Headlines

How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
Where Edgewise Therapeutics Stands With Analysts
Edgewise Therapeutics (EWTX) Receives a Buy from Truist Financial
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
Edgewise Therapeutics (EWTX) Gets a Sell from Goldman Sachs
See More Headlines
Receive EWTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edgewise Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

EWTX Company Calendar

Last Earnings
8/10/2023
Today
9/21/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EWTX
Fax
N/A
Employees
74
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$27.00
High Stock Price Forecast
$29.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+335.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-67,640,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.48 per share

Miscellaneous

Free Float
43,184,000
Market Cap
$393.45 million
Optionable
Not Optionable
Beta
-0.26
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Peter A. Thompson FACP (Age 63)
    M.D., Co-Founder & Independent Chairman
    Comp: $73k
  • Dr. Kevin Koch Ph.D. (Age 63)
    Pres, CEO & Director
    Comp: $913.1k
  • Dr. Badreddin Edris Ph.D. (Age 36)
    Co-Founder & Independent Director
    Comp: $40k
  • Dr. Alan J. Russell Ph.D. (Age 53)
    Co-Founder, Chief Scientific Officer & Director
    Comp: $657.52k
  • Dr. Joanne M. Donovan M.D. (Age 66)
    Ph.D., Chief Medical Officer
    Comp: $695.48k
  • Mr. R. Michael Carruthers (Age 65)
    Chief Financial Officer
  • Mr. John R. Moore (Age 59)
    Gen. Counsel
  • Dr. Behrad Derakhshan Ph.D. (Age 43)
    Chief Bus. Officer
  • Dr. Marc Semigran M.D. (Age 66)
    Chief Devel. Officer













EWTX Stock - Frequently Asked Questions

Should I buy or sell Edgewise Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Edgewise Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EWTX shares.
View EWTX analyst ratings
or view top-rated stocks.

What is Edgewise Therapeutics' stock price forecast for 2023?

4 analysts have issued 12-month price objectives for Edgewise Therapeutics' shares. Their EWTX share price forecasts range from $25.00 to $29.00. On average, they expect the company's stock price to reach $27.00 in the next year. This suggests a possible upside of 335.5% from the stock's current price.
View analysts price targets for EWTX
or view top-rated stocks among Wall Street analysts.

How have EWTX shares performed in 2023?

Edgewise Therapeutics' stock was trading at $8.94 at the start of the year. Since then, EWTX shares have decreased by 30.6% and is now trading at $6.20.
View the best growth stocks for 2023 here
.

When is Edgewise Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our EWTX earnings forecast
.

How were Edgewise Therapeutics' earnings last quarter?

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) released its quarterly earnings results on Thursday, August, 10th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.07.

What ETF holds Edgewise Therapeutics' stock ?

iShares Neuroscience and Healthcare ETF holds 4,907 shares of EWTX stock, representing 0.70% of its portfolio.

When did Edgewise Therapeutics IPO?

(EWTX) raised $150 million in an IPO on Friday, March 26th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, SVB Leerink and Wedbush PacGrow served as the underwriters for the IPO.

What is Edgewise Therapeutics' stock symbol?

Edgewise Therapeutics trades on the NASDAQ under the ticker symbol "EWTX."

Who are Edgewise Therapeutics' major shareholders?

Edgewise Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.95%), Deep Track Capital LP (4.33%), Goldman Sachs Group Inc. (2.76%), Geode Capital Management LLC (1.35%), State Street Corp (1.18%) and Granahan Investment Management LLC (1.02%). Insiders that own company stock include Alan J Russell, Behrad Derakhshan, Holdings A/S Novo, James E Flynn, Joanne M Donovan, John R Moore, Jonathan D Root, Kevin Koch, Orbimed Advisors Llc, Peter A Thompson and R Michael Carruthers.
View institutional ownership trends
.

How do I buy shares of Edgewise Therapeutics?

Shares of EWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Edgewise Therapeutics' stock price today?

One share of EWTX stock can currently be purchased for approximately $6.20.

How much money does Edgewise Therapeutics make?

Edgewise Therapeutics (NASDAQ:EWTX) has a market capitalization of $393.45 million. The company earns $-67,640,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis.

How can I contact Edgewise Therapeutics?

Edgewise Therapeutics' mailing address is 3415 COLORADO AVE., BOULDER CO, 80303. The official website for the company is www.edgewisetx.com. The company can be reached via phone at 720-262-7002 or via email at ir@edgewisetx.com.

This page (NASDAQ:EWTX) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -